acquired
Stage
1
Investors
About
Halda Therapeutics develops RIPTAC therapeutics, a novel class of precision cancer medicines that selectively kill cancer cells by inducing targeted protein-protein interactions.
Explore Halda Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.